Beta Amyloid PET/CT in Various Aβ-Related Disease

NCT06725706 | Recruiting

• 1 other identifier: TJMUGH-07
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 3

Brief Summary

To evaluate the potential usefulness of 18F-92/AV45, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.

Conditions

Amyloid; Beta-Amyloid; Neurodegenerative Diseases

Keywords

PET/CT; MRI; Beta-Amyloid

Outcome Measures

Primary Outcomes (1)

• Standardized uptake value (SUV)

  Standardized uptake value (SUV) of 18F-92/AV45, 11C-PIB for each target lesion of subject or suspected primary tumor or/and metastasis.

  30 days

Secondary Outcomes (1)

• Diagnostic efficacy

  30 days

Study Arms (1)

Single Group Assignment

Each subject receive a single intravenous injection of 18F-92/AV45, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time.

Diagnostic Test: 18F-92/AV45, 11C-PIB

Interventions

18F-92/AV45, 11C-PIB DIAGNOSTIC_TEST

Each subject receive a single intravenous injection of 18F-92/AV45, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time.

Single Group Assignment

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

(i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Aβ PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

You may qualify if:

• \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Aβ PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

You may not qualify if:

• \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Sponsors & Collaborators

• Tianjin Medical University: lead
• Tianjin Medical University General Hospital: collaborator

Study Sites (3)

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, 230000, China

RECRUITING

Chinese PLA General Hospital,

Beijing, Beijing Municipality, 100853, China

RECRUITING

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China

RECRUITING

Related Publications (1)

• Li Y, Pan M, Yu H, Zhang Q, Chang Y, Zhao H, Wang J, Wang X, Dai J, Yu L, Chen D, Zhang J, Yan XX, Yao S, Cui M. Preclinical and preliminary clinical evaluation of [18F]Florbetazine for non-invasive PET detection of cardiac amyloidosis. Eur J Nucl Med Mol Imaging. 2026 Jan 10. doi: 10.1007/s00259-025-07719-9. Online ahead of print.

  PMID: 41518400 DERIVED

MeSH Terms

Conditions

Alzheimer Disease; Plaque, Amyloid; Neurodegenerative Diseases

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurocognitive Disorders; Mental Disorders; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Ying Wang, MD

CONTACT

+8618702292537; macrossplusvoices@163.com

Li Cai, MD

CONTACT

+862260362190; xcl242004@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 7 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof.

Study Record Dates

• First Submitted: December 5, 2024
• First Posted: December 10, 2024
• Study Start: September 1, 2012
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: June 4, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (3)